{"id":238717,"date":"2026-09-09T16:00:42","date_gmt":"2026-09-09T10:30:42","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=238717"},"modified":"2026-09-09T16:00:42","modified_gmt":"2026-09-09T10:30:42","slug":"is-cohance-lifesciences-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-cohance-lifesciences-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Cohance Lifesciences a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Cohance Lifesciences share price around Rs 443. 57.4% below 52-week high of Rs 1,039. Q1 FY27 revenue Rs 435 crore, down 22.9% YoY. loss of Rs 45 crore.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Cohance Lifesciences swung to a net loss of Rs 45 crore in Q1 FY27, as revenue also fell 22.9% to Rs 435 crore. This is a meaningful shift from the year-ago quarter, and the Cohance Lifesciences share price should be evaluated against this profitability reset rather than the topline trend alone before calling it a good buy.<\/p>\n<\/p><\/div>\n

The Cohance Lifesciences share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Cohance Lifesciences is formerly Suven Pharmaceuticals, a pharma CDMO and specialty ingredients company following its merger with Cohance Lifesciences, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 435 crore, down 22.9% year on year, while the company reported a net loss of Rs 45 crore. That combination of numbers is exactly what this article breaks down, along with what it means for the Cohance Lifesciences share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Cohance Lifesciences share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n